The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

By Ludwig Burger and Ariane Luthi (Reuters) -Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

Blackstone Life Sciences has sold Anthos Therapeutics to Novartis for up to $3.1 billion. Anthos is a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the ...

Swiss pharmaceutical giant Novartis has agreed to acquire Anthos Therapeutics, a biopharma firm majority-owned by ...

Novartis (NVS) has sealed a $3.1 billion deal to acquire clinical-stage biopharmaceutical company Anthos Therapeutics. The ...

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...